Study S002787

An Open-label, Single-sequence, Crossover Study Investigating the Influence of UBT251 on Pharmacokinetics of Index Substrates for Cytochrome P450 Enzymes in Participants With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07710768
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: RECRUITING
Enrollment: 44
Start: 2026-07-15
Primary completion: 2027-04-07
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity; Overweight
Interventions: DRUG:UBT251; DRUG:Cocktail (Warfarin/Caffeine/Midazolam)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1332-5554

Registered primary outcomes

AUC0-∞,s-warfarin: The area under the plasma s-warfarin concentration-time curve extrapolated to infinity after single dose [From pre-dose on Day 1 up to 156 days]
AUC0-∞,caffeine : The area under the plasma caffeine concentration-time curve extrapolated to infinity after single dose [From pre-dose on Day 1 up to 156 days]
AUC0-∞,midazolam: The area under the midazolam concentration-time curve extrapolated to infinity after single dose [From pre-dose on Day 1 up to 156 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.